Report Detail
Interventional Cardiology Global Market
- RnM2895575 |
- 12 March, 2020 |
- Global |
- 511 Pages |
- IQ4I Research & Consultancy |
- Medical Devices & Consumables
Interventional cardiology specifically deals with the catheter based treatment of cardiovascular and structural heart diseases. Products of interventional cardiology market are Catheters, Interventional Diagnostic Catheters, stents, valves, transcatheter heart pump and others. Catheters are segmented into Guide Catheter, Balloon Catheter, Atherectomy Catheters, Thrombectomy Catheters, and Ablation Catheters. Interventional Diagnostic Catheters are segmented into Intravascular ultrasound (IVUS), Fractional flow reserve (FFR), Optical coherence tomography (OCT), Angiograph, Pulmonary artery catheter, Electrophysiology catheter. Stents are further categorised into bare metal stents, drug eluting stents, Bioresorbable stents and Stent grafts. Valves are further divided into Transcatheter Aortic Valve, Annuloplasty Ring, Mitral Clip, and Valvuloplasty. Others are segmented into closure devices (Occluders), Inferior vena cava filters, Guide wires, Transcatheter pacemaker, and accessories.
Applications of Interventional cardiology market are segmented into Diagnostic catheterization, Coronary Interventions, Peripheral interventions and Structural Heart. Coronary intervention application is sub-segmented into Aortic aneurysm (EAVR, TEVAR), Coronary Thrombectomy, PCTA, Coronary Cardiac Ablation and others. Peripheral interventions are sub-segmented into Peripheral Aneurysm, Peripheral Thrombectomy, Peripheral Angioplasty, Peripheral Ablation, Pulmonary embolism, and others. Structural heart is further sub-segmented into Valve replacement, Valve repair, Heart Assist Device, Congenital heart defect and others.
The interventional cardiology global market is expected to grow at a CAGR of high single digit CAGR to reach $46,124.1 million by 2023. Among the Interventional cardiology products, the stents market dominated the products market by occupying a largest share. At the same time, Transcatheter heart pump market is the fastest growing segment projected to grow at a high double digit CAGR. In applications, Coronary Interventions is the largest segment and Structural Heart is the fastest growing segment with the strong CAGR.
Geographical wise, North America is the largest market followed by Europe and Asia-Pacific. The APAC region is projected to be the fastest growing region suggesting an opportunities for growth and likely to get attention of new investors in the interventional cardiology market. Growth in the Asian market is attributed to rising prevalence of lifestyle diseases, ageing population and government initiatives in establishing innovative technologies.
Increasing incidences of cardiovascular diseases due to change in lifestyle, Demand for minimally invasive treatment due to less complication, Rise in the number of Cardiovascular disorders and ageing population, awareness of minimally invasive procedures and newly invented devices, raise in number of clinical studies performed are some of the drivers in the Interventional cardiology global market. Many entry level barriers, stringent regulation and lack of skilled and trained professionals are some of the factors hampering the growth of Interventional cardiology market.
The interventional cardiology global market is a consolidated, highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the interventional cardiology market are Abbott Laboratories (U.S.), Boston Scientific (U.S.), B. Braun Melsungen AG (Germany), C.R. Bard, Inc. (U.S.), Edwards Lifesciences (U.S.), Medtronic PLC (Ireland), Terumo Corporation (Japan), Johnson & Johnson (U.S.).
1 EXECUTIVE SUMMARY 32
2 INTRODUCTION 37
- 2.1 KEY TAKEAWAYS 37
- 2.2 REPORT DESCRIPTION 38
- 2.3 MARKETS COVERED 40
- 2.4 STAKEHOLDERS 42
- 2.5 RESEARCH METHODOLOGY 42
- 2.5.1 MARKET SIZE ESTIMATION 44
- 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 46
- 2.5.3 SECONDARY SOURCES 47
- 2.5.4 PRIMARY SOURCES 48
- 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 48
- 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 49
- 2.5.7 ASSUMPTIONS 49
3 MARKET ANALYSIS 51
- 3.1 INTRODUCTION 51
- 3.2 MARKET SEGMENTATION 52
- 3.3 FACTORS INFLUENCING MARKET 54
- 3.3.1 DRIVERS AND OPPORTUNITIES 55
- 3.3.1.1 Increase in prevalence of cardiovascular disorders due to rise
in aging population 55
- 3.3.1.2 Increasing number of interventional procedures 55
- 3.3.1.3 Rise in the number of clinical studies performed 56
- 3.3.1.4 Increasing prevalence of lifestyle diseases 57
- 3.3.1.5 Technology advancements and growing healthcare budgetary allocation 58
- 3.3.1.6 Growth in emerging countries 59
- 3.3.1.7 Increase in patient awareness for minimal invasive surgeries 60
- 3.3.1 DRIVERS AND OPPORTUNITIES 55
- 3.3.2 RESTRAINTS AND THREATS 61
- 3.3.2.1 Stringent regulatory requirements with high cost of development 61
- 3.3.2.2 Lack of skilled and trained professionals 61
- 3.3.2.3 Availability of alternatives products and procedures 62
- 3.3.2.4 Reimbursement issues in emerging countries 63
- 3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 64
- 3.4.2 U.S. 64
- 3.4.3 CANADA 65
- 3.4.4 EUROPE 66
- 3.4.5 CHINA 66
- 3.4.6 JAPAN 67
- 3.4.7 INDIA 68
- 3.5.1 REIMBURSEMENT TABLE 70
- 3.5.1.1 Diagnostic cardiac catheterization 70
- 3.5.1.2 Coronary angioplasty (PTCA), without stent 75
- 3.5.1.3 Coronary atherectomy (PTCA), without stent 76
- 3.5.1.4 Non-drug-eluting stent with angioplasty (PTCA) 77
- 3.5.1.5 Drug-eluting stent with angioplasty (PTCA) 77
- 3.5.1.6 Non drug-eluting stent with atherectomy 78
- 3.5.1.7 Drug-eluting stent with atherectomy 79
- 3.5.1.8 Non-drug-eluting stent coronary revascularization 80
- 3.5.1.9 Acute myocardial infarction 81
- 3.5.1.10 Chronic total occlusion 81
- 3.5.1.11 Drug-eluting stent coronary revascularization 82
- 3.5.1.12 Acute myocardial infarction 83
- 3.5.1.13 Chronic total occlusion 84
- 3.5.1.14 Intravascular ultrasound 85
- 3.5.1.15 Fractional flow reserve 86
- 3.5.1.16 Intravascular ultrasound (peripheral interventions) 87
- 3.5.1.17 Percutaneous balloon valvuloplasty; aortic valve 87
- 3.5.1.18 Endovascular or transthoracic valves 88
- 3.5.1.19 Watchman tm left atrial appendage closure (LAAC) procedure 91
- 3.5.1.20 Thrombectomy 92
- 3.5.1.21 Aneurysm 93
- 3.8.1 INTRODUCTION 116
- 3.8.2 CARDIAC OR VENTRICULAR REMODELLING AND HEART PUMP 116
- 3.8.3 TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) 117
- 3.9.1 THREAT OF NEW ENTRANTS 119
- 3.9.2 THREAT OF SUBSTITUTES 119
- 3.9.3 BARGAINING POWER OF SUPPLIERS 120
- 3.9.4 BARGAINING POWER OF BUYERS 120
- 3.9.5 COMPETITIVE RIVALRY 121
4 INTERVENTIONAL CARDIOLOGY GLOBAL MARKET, BY PRODUCT 131
- 4.1 INTRODUCTION 131
- 4.2 CATHETERS 134
- 4.2.1 GUIDE CATHETER 140
- 4.2.2 BALLOON CATHETERS 142
- 4.2.3 ATHERECTOMY CATHETERS 144
- 4.2.3.1 Directional atherectomy catheter 146
- 4.2.3.2 Rotational atherectomy catheter 146
- 4.2.3.3 Orbital atherectomy catheter 147
- 4.2.3.4 Laser atherectomy catheter 147
- 4.2.4 THROMBECTOMY CATHETERS 148
- 4.2.5 ABLATION CATHETERS 150
- 4.2.5.1 Radiofrequency ablation 151
- 4.2.5.2 Others 152
- 4.3 INTERVENTIOAL DIAGNOSTIC CATHETERS 153
- 4.3.1 INTRAVASCULAR ULTRASOUND (IVUS) CATHETER 158
- 4.3.2 FRACTIONAL FLOW RESERVE (FFR) CATHETER 160
- 4.3.3 OPTICAL COHERENCE TOMOGRAPHY (OCT) CATHETER 162
- 4.3.4 ANGIOGRAPHIC CATHETER 164
- 4.3.5 PULMONARY ARTERY CATHETER (PAC) 166
- 4.3.6 ELECTROPHYSIOLOGY CATHETER 168
- 4.4 STENTS 170
- 4.4.1 BARE METAL STENTS 175
- 4.4.2 DRUG ELUTING STENTS 178
- 4.4.3 BIORESORBABLE STENTS 180
- 4.4.4 STENT GRAFTS 184
- 4.5 VALVES 186
- 4.5.1 TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) 191
- 4.5.2 ANNULOPLASTY RING 193
- 4.5.3 MITRAL CLIP 196
- 4.5.4 VALVULOPLASTY 198
- 4.6 TRANSCATHETER HEART PUMP 200
- 4.7 OTHERS 203
- 4.7.1 OCCLUDERS 207
- 4.7.2 INFERIOR VENA CAVA FILTERS 209
- 4.7.3 OTHERS 211
5 INTERVENTIONAL CARDIOLOGY GLOBAL MARKET, BY APPLICATION 213
- 5.1 INTRODUCTION 213
- 5.2 DIAGNOSTIC CATHETERIZATION 216
- 5.3 CORONARY INTERVENTIONS 218
- 5.3.1 AORTIC ANEURYSM 223
- 5.3.2 CORONARY THROMBECTOMY 225
- 5.3.3 PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) 227
- 5.3.4 CORONARY ABLATION 229
- 5.3.5 OTHER CORONARY INTERVENTIONS 231
- 5.4 PERIPHERAL INTERVENTIONS 233
- 5.4.1 PERIPHERAL ANEURYSM 238
- 5.4.2 PERIPHERAL THROMBECTOMY 240
- 5.4.3 PERIPHERAL ANGIOPLASTY 242
- 5.4.4 PERIPHERAL ABLATION 244
- 5.4.5 PULMONARY EMBOLISM 245
- 5.4.6 OTHER PERIPHERAL INTERVENTIONS 246
- 5.5 STRUCTURAL HEART 248
- 5.5.1 VALVE REPLACEMENT 253
- 5.5.2 VALVE REPAIR (MITRAL CLIP) 255
- 5.5.3 HEART ASSIST DEVICE 257
- 5.5.4 CONGENITAL HEART DEFECT 259
- 5.5.5 OTHERS 261
6 REGIONAL ANALYSIS 263
- 6.1 INTRODUCTION 263
- 6.2 NORTH AMERICA 266
- 6.2.1 U.S. 281
- 6.2.2 OTHERS 286
- 6.3 EUROPE 291
- 6.3.1 GERMANY 306
- 6.3.2 FRANCE 311
- 6.3.3 U.K. 316
- 6.3.4 OTHERS 321
- 6.4 APAC 326
- 6.4.1 JAPAN 341
- 6.4.2 CHINA 346
- 6.4.3 INDIA 351
- 6.4.4 OTHERS 356
- 6.5 ROW 361
- 6.5.1 BRAZIL 375
- 6.5.2 MIDDLE EAST 380
- 6.5.3 OTHERS 385
7 COMPANY DEVELOPMENTS 390
- 7.1 INTRODUCTION 390
- 7.2 APPROVALS 391
- 7.3 ACQUISITIONS AND MERGERS 405
- 7.4 NEW PRODUCT LAUNCH 409
- 7.5 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES 411
- 7.6 OTHER DEVELOPMENTS 413
8 MAJOR COMPANIES 414
- 8.1 ABBOTT LABORATORIES 414
- 8.1.1 OVERVIEW 414
- 8.1.2 FINANCIALS 415
- 8.1.3 PRODUCT PORTFOLIO 418
- 8.1.4 KEY DEVELOPMENTS 419
- 8.1.5 BUSINESS STRATEGY 421
- 8.1.6 SWOT ANALYSIS 422
- 8.2 ABIOMED 423
- 8.2.1 OVERVIEW 423
- 8.2.2 FINANCIALS 424
- 8.2.3 PRODUCT PORTFOLIO 426
- 8.2.4 KEY DEVELOPMENTS 426
- 8.2.5 BUSINESS STRATEGY 429
- 8.2.6 SWOT ANALYSIS 430
- 8.3 B.BRAUN MELSUNGEN AG 431
- 8.3.1 OVERVIEW 431
- 8.3.2 FINANCIALS 432
- 8.3.3 PRODUCT PORTFOLIO 435
- 8.3.4 KEY DEVELOPMENTS 436
- 8.3.5 BUSINESS STRATEGY 437
- 8.3.6 SWOT ANALYSIS 438
- 8.4 BOSTON SCIENTIFIC CORPOARTION 439
- 8.4.1 OVERVIEW 439
- 8.4.2 FINANCIALS 440
- 8.4.3 PRODUCT PORTFOLIO 444
- 8.4.4 KEY DEVELOPMENTS 448
- 8.4.5 BUSINESS STRATEGY 451
- 8.4.6 SWOT ANALYSIS 452
- 8.5 C.R.BARD INC. 453
- 8.5.1 OVERVIEW 453
- 8.5.2 FINANCIALS 454
- 8.5.3 PRODUCT PORTFOLIO 457
- 8.5.4 KEY DEVELOPMENTS 459
- 8.5.5 BUSINESS STRATEGY 460
- 8.5.6 SWOT ANALYSIS 461
- 8.6 COOK MEDICAL, INC. 462
- 8.6.1 OVERVIEW 462
- 8.6.2 FINANCIALS 463
- 8.6.3 PRODUCT PORTFOLIO 463
- 8.6.4 KEY DEVELOPMENTS 464
- 8.6.5 BUSINESS STRATEGY 465
- 8.6.6 SWOT ANALYSIS 466
- 8.7 EDWARDS LIFESCIENCES CORP. 467
- 8.7.1 OVERVIEW 467
- 8.7.2 FINANCIALS 468
- 8.7.3 PRODUCT PORTFOLIO 471
- 8.7.4 KEY DEVELOPMENTS 471
- 8.7.5 BUSINESS STRATEGY 474
- 8.7.6 SWOT ANALYSIS 475
- 8.8 JOHNSON & JOHNSON (BIOSENSE WEBSTER) 476
- 8.8.1 OVERVIEW 476
- 8.8.2 FINANCIALS 477
- 8.8.3 PRODUCT PORTFOLIO 480
- 8.8.4 KEY DEVELOPMENTS 481
- 8.8.5 BUSINESS STRATEGY 481
- 8.8.6 SWOT ANALYSIS 482
- 8.9 MEDTRONIC PLC 483
- 8.9.1 OVERVIEW 483
- 8.9.2 FINANCIALS 484
- 8.9.3 PRODUCT PORTFOLIO 488
- 8.9.4 KEY DEVELOPMENTS 490
- 8.9.5 BUSINESS STRATEGY 493
- 8.9.6 SWOT ANALYSIS 494
- 8.10 TERUMO CORPORATION 495
- 8.10.1 OVERVIEW 495
- 8.10.2 FINANCIALS 496
- 8.10.3 PRODUCT PORTFOLIO 499
- 8.10.4 KEY DEVELOPMENTS 501
- 8.10.5 BUSINESS STRATEGY 503
- 8.10.6 SWOT ANALYSIS 504
- 8.11 W.L. GORE & ASSOCIATES, INC. 505
- 8.11.1 OVERVIEW 505
- 8.11.2 FINANCIALS 506
- 8.11.3 PRODUCT PORTFOLIO 506
- 8.11.4 KEY DEVELOPMENTS 507
- 8.11.5 BUSINESS STRATEGY 509
Summary:
Get latest Market Research Reports on Interventional Cardiology . Industry analysis & Market Report on Interventional Cardiology is a syndicated market report, published as Interventional Cardiology Global Market . It is complete Research Study and Industry Analysis of Interventional Cardiology market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
